Development and Evaluation of Bilayer Sustained-Release Tablets of Ruxolitinib Using Discriminative Pharmacokinetic Analysis and IVIVC

<b>Objectives</b>: This study explores the development and evaluation of a bilayer sustained-release (SR) tablet formulation of ruxolitinib. As a BCS Class 1 drug, ruxolitinib requires twice-daily dosing due to its short half-life. We designed a bilayer tablet that integrates immediate-release (IR)...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Namhyuck Kim, Kyoungho Kim, Seungwei Jeong, Jiyeong Kim, Helen Cho, Young-Joo Lee, Sangyeob Park
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2025-03-01
coleção:	Pharmaceutics
Assuntos:	bilayer tablet sustained release formulation ruxolitinib IVIVC dissolution
Acesso em linha:	https://www.mdpi.com/1999-4923/17/4/432
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!